KYTX
Kyverna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.25
−1.20%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+10.4%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| May 29, 2026 | CLARK IAN T · director | A-Award | 5,093 | $0.00 |
| May 29, 2026 | Aktar Mert · director | A-Award | 20,582 | $8.59 |
| May 29, 2026 | Aktar Mert · director | A-Award | 5,093 | $0.00 |
| May 29, 2026 | Shaw Christi · director, officer: Executive Chairperson | F-InKind | 4,194 | $8.59 |
| May 29, 2026 | SEIDENBERG BETH C · director | A-Award | 20,582 | $8.59 |
| May 29, 2026 | SEIDENBERG BETH C · director | A-Award | 5,093 | $0.00 |
| May 29, 2026 | Cohen Fred E · director | A-Award | 20,582 | $8.59 |
| May 29, 2026 | Cohen Fred E · director | A-Award | 5,093 | $0.00 |
| May 29, 2026 | CLARK IAN T · director | A-Award | 20,582 | $8.59 |
| May 20, 2026 | Martini Gregory S. · officer: Chief Financial Officer | A-Award | 325,000 | $8.54 |
| May 6, 2026 | Dac Nadia · officer: Chief Commercial Officer | A-Award | 300,000 | $9.00 |
| Mar 17, 2026 | Biddle Warner Weston · director, officer: Chief Executive Officer | A-Award | 58,000 | $0.00 |
| Mar 17, 2026 | Biddle Warner Weston · director, officer: Chief Executive Officer | A-Award | 350,000 | $8.95 |
| Mar 17, 2026 | GRASSO MARC · officer: Chief Financial Officer | A-Award | 10,000 | $0.00 |
| Mar 17, 2026 | GEHCHAN NAJI · officer: See Remarks | A-Award | 105,000 | $8.95 |
| Mar 17, 2026 | GEHCHAN NAJI · officer: See Remarks | A-Award | 18,000 | $0.00 |
| Mar 17, 2026 | GRASSO MARC · officer: Chief Financial Officer | A-Award | 65,000 | $8.95 |
| Mar 4, 2026 | Miller Andrew Craig · director | A-Award | 11,006 | $0.00 |
| Mar 4, 2026 | Miller Andrew Craig · director | A-Award | 42,945 | $7.95 |
| Feb 26, 2026 | Emany Sravan Kumar · director | A-Award | 42,945 | $7.95 |
| Feb 26, 2026 | Emany Sravan Kumar · director | A-Award | 11,006 | $0.00 |
| Feb 11, 2026 | Pujols Mayobanex · officer: Chief Technology Officer | A-Award | 300,000 | $8.08 |
| Jan 14, 2026 | Shaw Christi · director, officer: Executive Chairperson | A-Award | 185,000 | $8.23 |
| Jan 14, 2026 | Shaw Christi · director, officer: Executive Chairperson | A-Award | 30,000 | $0.00 |
| Jan 14, 2026 | Shaw Christi · director, officer: Executive Chairperson | A-Award | 24,301 | $0.00 |
| Dec 22, 2025 | SEIDENBERG BETH C · director | Purchase | 133,333 | $7.50 |
| Dec 22, 2025 | Westlake BioPartners Opportunity Fund I, L.P. · 10 percent owner | Purchase | 133,333 | $7.50 |
| Dec 17, 2025 | Walker Karen Marie · officer: Chief Technology Officer | M-Exempt | 23,998 | $4.83 |
| Dec 17, 2025 | Walker Karen Marie · officer: Chief Technology Officer | Sale | 23,998 | $12 |
| Jul 1, 2025 | GRASSO MARC · officer: Chief Financial Officer | A-Award | 450,000 | $3.07 |
Institutional positioning
13F filings over the trailing two quarters
New 29Increased 32Reduced 36Sold out 110
| Filer | Action | Shares | Filed |
|---|---|---|---|
| GordonMD Global Investments LP | Reduced | 4,244,818 | May 15, 2026 |
| GILEAD SCIENCES, INC. | Unchanged | 4,126,119 | May 8, 2026 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | Unchanged | 3,110,000 | May 15, 2026 |
| AIGH CAPITAL MANAGEMENT LLC | Increased | 2,000,000 | Apr 30, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Unchanged | 2,000,000 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 1,783,342 | May 15, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Reduced | 1,555,287 | May 15, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Increased | 1,125,321 | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 1,005,508 | May 15, 2026 |
| INSIGHT HOLDINGS GROUP, LLC | Unchanged | 989,054 | May 15, 2026 |
| MORGAN STANLEY | Reduced | 977,289 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 877,078 | May 13, 2026 |
| WOODLINE PARTNERS LP | Increased | 845,325 | May 15, 2026 |
| D. E. SHAW & CO., INC. | Increased | 721,581 | May 15, 2026 |
| PROPEL BIO MANAGEMENT, LLC | Reduced | 644,421 | May 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing May 29, 2026